Use of Tissue Plasminogen Activator in the Clearance of Chronic Subdural Hematomas
The Utility of Intra-Catheter Fibrinolytics in Draining Chronic Subdural Hematomas: A Randomized Controlled Trial Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Dr. Kesava Reddy
- Phone Number: 905-521-0061
- Email: reddy@hhsc.ca
Study Contact Backup
- Name: Jessy Moore, MSc
- Phone Number: 289-686-8827
- Email: moorej@hhsc.ca
Study Locations
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Hamilton General Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adult patients (18 yrs or older)
- Admitted to neurosurgery wing at the hospital
- Symptomatic patients requiring surgical drainage by twist drill craniostomy
Exclusion Criteria:
- Patients at increased risk of bleeding such as patients taking anticoagulation medication that required reversal at time of intervention، or those with coagulopathic disorder.
- Patients on antiplatelets or anticoagulation medications (DOACs or warfarin) with appropriate holding period prior to drainage, those who are eventually minimized to a regular bleeding risk compared to the normal population, will be included in the study.
- Patients with subdural empyema.
- Redo twist drill craniostomy for residual cSDH within the same admission.
- Drain accidentally removed during nursing care or patient transport before 24 hr interval scan.
- Patients who are not expected to live more than three months.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention - tPA administered
This group will receive 2mL of intra-catheter tPA during twist drill craniostomy procedure
|
Dosage of 1mg/mL mixed in 0.9% saline solution, intra-catheter administration, sterile
|
|
Placebo Comparator: Placebo Control
This group will receive 2mL of intra-catheter saline solution during twist drill craniostomy procedure
|
0.9% saline solution, intra-catheter administration, sterile
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Study Feasibility
Time Frame: 8 months
|
Patient recruitment rate, eligibility of patients, protocol adherence, unexpected events
|
8 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Volume of chronic subdural hematoma
Time Frame: 8 months
|
Volume, as measured in 3 intervals: pre-procedure, post-procedure at 24hrs and 6 weeks
|
8 months
|
|
Rate of adverse events
Time Frame: 8 months
|
Rate of adverse events in the first 6 weeks post procedure, including CNS infection, seizure, post-op hemorrhage
|
8 months
|
|
Length of hospital stay
Time Frame: 8 months
|
length of hospital stay in days
|
8 months
|
|
Reoperation rate
Time Frame: 8 months
|
Reoperation rate or reintervention in the first 6 weeks post drainage
|
8 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Dr. Kesava Reddy, Hamilton Health Sciences Corporation
Publications and helpful links
General Publications
- Neils DM, Singanallur PS, Wang H, Tracy P, Klopfenstein J, Dinh D, Elwood PW, Fassett D, McCall T, Lin J, Tsung A. Recurrence-free chronic subdural hematomas: a retrospective analysis of the instillation of tissue plasminogen activator in addition to twist drill or burr hole drainage in the treatment of chronic subdural hematomas. World Neurosurg. 2012 Jul;78(1-2):145-9. doi: 10.1016/j.wneu.2011.08.032. Epub 2011 Nov 7.
- Brazdzionis J, Patchana T, Wiginton JG 4th, Wacker MR, Menoni R, Miulli DE. Intracatheter Tissue Plasminogen Activator for Chronic Subdural Hematomas after Failed Bedside Twist Drill Craniostomy: A Retrospective Review. Cureus. 2019 Dec 26;11(12):e6472. doi: 10.7759/cureus.6472.
- O YM, Tsang SL, Leung GK. Fibrinolytic-Facilitated Chronic Subdural Hematoma Drainage-A Systematic Review. World Neurosurg. 2021 Jun;150:e408-e419. doi: 10.1016/j.wneu.2021.03.029. Epub 2021 Mar 17.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Wounds and Injuries
- Pathologic Processes
- Craniocerebral Trauma
- Trauma, Nervous System
- Intracranial Hemorrhages
- Intracranial Hemorrhage, Traumatic
- Pathological Conditions, Signs and Symptoms
- Hematoma
- Hemorrhage
- Hematoma, Subdural
- Amino Acids, Peptides, and Proteins
- Proteins
- Biological Factors
- Hydrolases
- Enzymes
- Enzymes and Coenzymes
- Blood Proteins
- Endopeptidases
- Peptide Hydrolases
- Serine Endopeptidases
- Serine Proteases
- Plasminogen Activators
- Blood Coagulation Factors
- Tissue Plasminogen Activator
Other Study ID Numbers
Other Study ID Numbers
- 14724
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Patient data will be de-identified and the data will be analyzed as a whole before becoming available to other researchers.
De-identified IPD may be shared with other researchers if necessary based on occurrence of adverse events occurrence, circumstantial findings, etc.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.